C
Cora N. Sternberg
Researcher at Cornell University
Publications - 747
Citations - 57991
Cora N. Sternberg is an academic researcher from Cornell University. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 92, co-authored 663 publications receiving 48986 citations. Previous affiliations of Cora N. Sternberg include CTO Hospital & North Shore University Hospital.
Papers
More filters
Journal ArticleDOI
Enzalutamide, an oral androgen receptor inhibitor for treatment of castration-resistant prostate cancer.
TL;DR: A review summarizes the body of evidence supporting enzalutamide efficacy and safety in CRPC and indicates that patients with nonmetastatic CRPC who have previously received docetaxel are likely to benefit from enzAlutamide treatment.
Journal ArticleDOI
Final results of EORTC intergroup randomized phase III trial comparing immediate versus deferred chemotherapy after radical cystectomy in patients with pT3T4 and/or N+ M0 transitional cell carcinoma (TCC) of the bladder.
Cora N. Sternberg,I. Skoneczna,J.M. Kerst,Sophie D. Fosså,Peter Albers,Mads Agerbæk,Herlinde Dumez,Maria De Santis,Christine Theodore,M. G. Leahy,John D. Chester,Antony Verbaeys,A. Caty,Gedske Daugaard,Sandrine Marreaud,Samantha Cambier,Richard Sylvester +16 more
TL;DR: This randomized intergroup phase III trial compared immediate vs deferred chemotherapy after radical cystectomy in pts with pT3T4 and/or N+ M0 TCC of the bladder with poor overall survival.
Journal ArticleDOI
Final overall survival (OS) from PROSPER: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC).
Cora N. Sternberg,Karim Fizazi,Fred Saad,Neal D. Shore,Ugo De Giorgi,David F. Penson,Ubirajara Ferreira,Petro Ivashchenko,Eleni Efstathiou,Katarzyna Madziarska,Michael Kolinsky,Daniel de Iracema Gomes Cubero,Bettina Noerby,Fabian Zohren,Xun Lin,Katharina Modelska,Jennifer Sugg,Joyce Steinberg,Maha Hussain +18 more
TL;DR: Achievement in metastasis-free survival with PROSPER improves upon previous studies by at least 50% and up to 100% in women with previously undiagnosed breast cancer.
Journal ArticleDOI
LBA24 TROPHY-U-01 cohort 1 final results: A phase II study of sacituzumab govitecan (SG) in metastatic urothelial cancer (mUC) that has progressed after platinum (PLT) and checkpoint inhibitors (CPI)
Y. Loriot,Arjun Vasant Balar,Daniel P. Petrylak,Scott T. Tagawa,Arash Rezazadeh,Aude Flechon,Rohit Jain,Neeraj Agarwal,Manojkumar Bupathi,Philippe Barthélémy,P. Beuzeboc,Phillip L. Palmbos,Christos Kyriakopoulos,D. Pouessel,Cora N. Sternberg,Q. Hong,T. Goswami,L.M. Itri,Petros Grivas +18 more
Journal ArticleDOI
High-risk metastatic urothelial cancer: chances for cure?
Fabio Calabrò,Cora N. Sternberg +1 more
TL;DR: New therapeutic strategies, such as molecular targeted small molecule therapy and monoclonal antibodies, and new molecular markers predictive of response have the potential to be incorporated into the current treatment strategies, increasing the rate of cure.